Is It Too Late to Buy JNJ After Blowout Earnings?

💡 Key Takeaway

JNJ's strong earnings and raised guidance confirm its solid fundamentals, but its elevated valuation suggests waiting for a dip may be prudent for value-focused investors.

What Happened: JNJ Delivers Blowout Quarter

Johnson & Johnson reported a strong earnings beat last week, with total revenue rising over 6% to $25 billion. The company raised its full-year sales guidance to $101.1 billion and adjusted earnings per share to $11.68, up from previous estimates.

Key growth drivers included immunology drug Tremfya, which soared 72% to $2 billion, and multiple myeloma drug Darzalex, up 18% to $4.2 billion. These gains helped offset declines from Stelara, which faces generic competition after losing exclusivity.

J&J's medtech division faced a headwind: sales of Abiomed heart pumps slipped after a study questioned Impella pump use in high-risk procedures. CFO Joseph Wolk said new data expected in early 2025 should alleviate concerns.

The company's broad portfolio of 28 products or platforms each generating over $1 billion in revenue provides a strong foundation for continued growth.

icon

What This Means for Me

If you hold JNJ, the strong earnings confirm its stability, but consider trimming if the stock becomes overweight due to price appreciation. For investors without JNJ, waiting for a dip may offer a better risk-reward, though dividend growth investors might still buy at current levels. The medtech headwind is minor but worth monitoring.

Why It Matters: Strong Fundamentals, But Valuation Gives Pause

JNJ's earnings report reinforces its status as a reliable growth stock in healthcare. The company's ability to offset Stelara losses with newer drugs like Tremfya and Darzalex demonstrates a strong pipeline and successful execution.

However, the stock is trading near its highest forward earnings multiple in recent history. This elevated valuation could lead to a pullback, especially if market sentiment shifts or if the medtech headwind persists.

For long-term investors, JNJ's Dividend King status (50+ years of dividend increases) and diversified revenue streams make it a compelling hold. But value investors may want to wait for a better entry point.

The raised guidance signals management's confidence, but the stock's recent run-up means much of the good news may already be priced in.

icon

Stock to Watch

StocksImpactAnalysis
JNJ
Positive
Blowout earnings, raised guidance, strong drug sales offset Stelara declines, and diversified portfolio support long-term growth.
KVUE
Neutral
As J&J's consumer health spinoff, KVUE benefits from the strategic focus but no direct earnings impact from JNJ's report.

Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.

icon

Bobby Insight

bobby-insight

JNJ is a solid long-term hold, but wait for a dip if you're a value investor.

The stock's strong fundamentals and dividend growth make it attractive for income-focused investors, but its high valuation suggests limited near-term upside. A pullback could provide a better entry point.

What This Means for Me

means-for-me
If you hold JNJ, the strong earnings confirm its stability, but consider trimming if the stock becomes overweight due to price appreciation. For investors without JNJ, waiting for a dip may offer a better risk-reward, though dividend growth investors might still buy at current levels. The medtech headwind is minor but worth monitoring.

Read More